Literature DB >> 16277174

Cardiovascular risk in aging and obesity: is there a role for GH.

M Gola1, S Bonadonna, M Doga, G Mazziotti, A Giustina.   

Abstract

GH has significant impact in adults. In fact, patients with the GH deficiency (GHD) syndrome are now recognized as having an increased cardiovascular risk. The effects of human aging on GH secretion have been evaluated by a number of researchers. Studies of 24 h secretion of GH have shown variable reductions in most 24-h GH secretory parameters in middle-aged and in older men and women, resulting in a decrease in plasma levels of its anabolic mediator IGF-I. Obesity is also associated with several endocrine and metabolic abnormalities. These include decreased serum GH concentrations, reduced GH half-life, frequency of GH secretory episodes and daily GH production rate. The mechanism of the low GH in obesity is not completely understood nor is it clear whether its relationship with visceral adiposity is causal. The aim of this article will be to review the available clinical data concerning the potential involvement of "subclinical" or perhaps better "functional" GHD, which is observed in aging and obesity, in the increase in cardiovascular risk which characterizes these two conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16277174     DOI: 10.1007/bf03347561

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  73 in total

1.  Beneficial effect on average lipid levels from energy restriction and fat loss in obese individuals with or without type 2 diabetes.

Authors:  T P Markovic; L V Campbell; S Balasubramanian; A B Jenkins; A C Fleury; L A Simons; D J Chisholm
Journal:  Diabetes Care       Date:  1998-05       Impact factor: 19.112

Review 2.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

Authors:  A Giustina; J D Veldhuis
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

3.  Effects of growth hormone administration on protein dynamics and substrate metabolism during 4 weeks of dietary restriction in obese women.

Authors:  H Nørrelund; J Børglum; J O Jørgensen; B Richelsen; N Møller; K S Nair; J S Christiansen
Journal:  Clin Endocrinol (Oxf)       Date:  2000-03       Impact factor: 3.478

4.  Age and secretagogue type jointly determine dynamic growth hormone responses to exogenous insulin-like growth factor-negative feedback in healthy men.

Authors:  Johannes D Veldhuis; Judith Y Weltman; Arthur L Weltman; Ali Iranmanesh; Eugenio E Muller; Cyril Y Bowers
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

5.  Impaired growth hormone response to growth hormone releasing factor and insulin-hypoglycaemia in obesity.

Authors:  P G Kopelman; K Noonan; R Goulton; A J Forrest
Journal:  Clin Endocrinol (Oxf)       Date:  1985-07       Impact factor: 3.478

6.  Contributions of gender and systemic estradiol and testosterone concentrations to maximal secretagogue drive of burst-like growth hormone secretion in healthy middle-aged and older adults.

Authors:  Johannes D Veldhuis; James T Patrie; Kimberly T Brill; Judith Y Weltman; Eugenio E Mueller; Cyril Y Bowers; Arthur Weltman
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

7.  Effects of human growth hormone in men over 60 years old.

Authors:  D Rudman; A G Feller; H S Nagraj; G A Gergans; P Y Lalitha; A F Goldberg; R A Schlenker; L Cohn; I W Rudman; D E Mattson
Journal:  N Engl J Med       Date:  1990-07-05       Impact factor: 91.245

8.  Short-term treatment with low doses of recombinant human GH stimulates lipolysis in visceral obese men.

Authors:  Paola Lucidi; Natascia Parlanti; Federica Piccioni; Fausto Santeusanio; Pierpaolo De Feo
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

9.  Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity.

Authors:  Stewart G Albert; Arshag D Mooradian
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

10.  Mechanisms of insulin resistance in aging.

Authors:  R I Fink; O G Kolterman; J Griffin; J M Olefsky
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

View more
  6 in total

1.  Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency.

Authors:  Linman Li; Wei Ren; Jinchao Li; Jingjing Liu; Lingli Wang; Xiaoya Zheng; Dezhen Liu; Sufang Li; Rhonda Souvenir; Jiping Tang
Journal:  Endocrine       Date:  2012-05-29       Impact factor: 3.633

Review 2.  The metabolic effects of growth hormone in adipose tissue.

Authors:  Valéria Ernestânia Chaves; Fernando Mesquita Júnior; Gisele Lopes Bertolini
Journal:  Endocrine       Date:  2013-02-21       Impact factor: 3.633

3.  Insulin-like growth factor I (IGF-1) deficiency ameliorates sex difference in cardiac contractile function and intracellular Ca(2+) homeostasis.

Authors:  Asli F Ceylan-Isik; Qun Li; Jun Ren
Journal:  Toxicol Lett       Date:  2011-07-07       Impact factor: 4.372

Review 4.  Glucocorticoids and the regulation of growth hormone secretion.

Authors:  Gherardo Mazziotti; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

5.  Deficiency of insulin-like growth factor 1 reduces sensitivity to aging-associated cardiomyocyte dysfunction.

Authors:  Qun Li; Asli F Ceylan-Isik; Ji Li; Jun Ren
Journal:  Rejuvenation Res       Date:  2008-08       Impact factor: 4.663

6.  Deficiency of insulin-like growth factor 1 reduces vulnerability to chronic alcohol intake-induced cardiomyocyte mechanical dysfunction: role of AMPK.

Authors:  Wei Ge; Qun Li; Subat Turdi; Xiao-Ming Wang; Jun Ren
Journal:  J Cell Mol Med       Date:  2011-08       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.